INFORMATION RESOURCES

 


PKD Foundation
pkdcure.org

American Kidney Fund
kidneyfund.org/kidney-disease/other-kidney-conditions/polycystic-kidney-disease.html

National Kidney Foundation
kidney.org

NORD (National Organization for Rare Diseases)
rarediseases.org

NIH Institute of Diabetes and Digestive and Kidney Diseases
niddk.nih.gov/health-information/kidney-disease

ARPKD/CHF Alliance
arpkdchf.org

American Association of Kidney Patients
aakp.org

 

Essential Reading List

Autosomal Dominant Polycystic Kidney Disease
Granthan JJ
NEJM 359; 14 - October 2, 2008

Volume Progression in Polycystic Kidney Disease
Granthan JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, and Miller JP, for the CRISP Investigators
NEJM 354; 20 - May 18, 2006

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, and Czerwiec FS, for the TEMPO 3:4 Trial Investigators
NEJM 367; 25 - December 20, 2012

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database 
Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, and Zimmer CA
Drug Saf 38:1103–1113 – July 2015

Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure
Endo M, Katayama K, Matsuo H, Horiike S, Nomura S, Hayashi A, Ishikawa E, Harada T, Sugimoto R, Tanemura A, Sugimoto K, Isaji S and Ito M
Kidney Int Reports 4:11, 1653–1657 – November 2019

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling
Woodhead JL, Pellegrini L, Shoda LKM, and Howell BA
Pharm Res 37:24 – January 2020

Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model
Wang X, Constans MM, Chebib FT, Torres VE, and Pellegrini L
Am J Nephrol. 49(6):487-493 – May 2019

Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
Di Mise A, Venneri M, Ranieri M, Centrone M, Pellegrini L, Tamma G, and Valenti G
Int J Mol Sci 26;21(1) – December 2019

Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, and Chapman AB, for the HALT-PKD Trial Investigators
NEJM 371; 24 - December 11, 2014

Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, and Perrone RD, for the HALT-PKD Trial Investigators
NEJM 371; 24 - December 11, 2014